Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for Tukysa

Release date: 2024-07-09 15:56:22     Recommended: 66

03L1072_24 图卡替尼 批文_00.jpg

TUKYSA is applicable to advanced unresectable or metastatic HER2 positive (including brain metastasis) breast cancer and RAS wild type, HER2 positive or metastatic colorectal cancer. Combined treatment with trastuzumab in adult patients with RAS wild-type, HER2 positive, or metastatic colorectal cancer who have progressed after chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan.

Company News

Research News

Drug news